



## ICoLA 2019

The 8<sup>th</sup> International Congress on Lipid & Atherosclerosis (ICoLA)  
The 58<sup>th</sup> Conference of the Korean Society of Lipid & Atherosclerosis (KSoLA)

September 5(Thu.) ~ 7(Sat.), 2019, Conrad Hotel Seoul, Republic of Korea

# Treatment Approach for Type 2 Diabetes Considering the Stable Glycemic Control

**So Hun Kim**

*Department of Internal Medicine, Inha University School of Medicine, Korea*

*shoney@inha.ac.kr*

---

### **Abstract**

Larger glycemic variability can contribute to the development of diabetic microvascular and macrovascular complications through mechanisms including increased oxidative stress, endothelial dysfunction and inflammation. Elevated glycemic variability has been shown to be an independent determinant of coronary artery disease and to be associated with worse cardiovascular outcomes and mortality. Increase glycemic variability also contributed to increased development of albuminuria and ESRD. The DPP4 inhibitors have been shown to have beneficial effect on glycemic variability compared to sulfonylureas or thiazolidinediones in previous studies. Results of the STABLE studies examining the effect of gemigliptin on glycemic variability compared to other drugs will be presented.

### **Keywords**

---

*Glycemic variability, Gemigliptin, DPP4 inhibitor*

---

**Secretariat** People & Value, Inc., #1001 161-17 Magokjungang-ro, Gangseo-gu, Seoul 07788, Republic of Korea

Tel : +82-2-2135-3617 Fax : +82-2-564-2123 E-mail : [secretariat@icola.org](mailto:secretariat@icola.org)